Navigation Links
Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
Date:2/13/2008

passcode 72272011. A replay of this call will be available until February 27, 2008 by phone at 1-888-286-8010 (U.S.), or 1-617-801-6888 (international), using the passcode 23908777.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information see http://www.JazzPharmaceuticals.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements, including, but not limited to, statements related to the anticipated regulatory approval and planned commercial launch of LUVOX CR and the continued development of Jazz Pharmaceuticals' product candidates. These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. Jazz Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, the risk that the FDA may not approve LUVOX CR for marketing in the United States; risks related to the launch of LUVOX CR; risks related to the development of Jazz Pharmaceuticals' product candidates, including the risk that study or clinical trial results may require Jazz Pharmaceuticals to discontinue the development of one or more product candidates; and risks related to the uncertain and time-consuming regulatory approval process. These and other risk factors are discussed under "Risk Factors" in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2007 filed by Jazz Pharmaceuticals with the Securities and Exchange Commission on November 9, 2007. Jazz Pharmaceuticals undertakes no duty or obligati
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
2. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
3. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
4. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
5. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
6. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
7. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
8. Jazz Pharmaceuticals, Inc. Announces Changes to its Board of Directors
9. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
11. Jazz Pharmaceuticals, Inc. to Announce Third Quarter 2007 Financial Results on November 6, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... for a number of breakthroughs, which altered the course ... paper, which laid the foundation of computer science, providing ... next played a pivotal role in the Second World ... codes, enabling the Allies to defeat the Nazis in ... turned his attention to artificial intelligence and proposed a ...
(Date:7/31/2014)... COLORADO SPRINGS, Colo. , July 31, 2014 ... Seed Grant awardee today with $25,000 to fund ... the Foundation,s inception in 2011, the gift was ... 11 th Annual Meeting in ... physicians who specialize in neurointerventional approaches to neurovascular ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 North Shore Towers, ... City, partnered with GI Energy, one of the nation’s leading ... $13 million upgrade of its 43-year-old CHP system. The original ... in an effort to extend the life of the plant, ... and associated electrical and heat recovery equipment, while maintaining continuous ...
(Date:7/31/2014)... 31, 2014 Senomyx , Inc. ... using proprietary taste science technologies to discover, develop, ... beverage, and ingredient supply industries, today reported financial ... ended the second quarter with $33.6 million in ... "During the past quarter Senomyx achieved another important ...
Breaking Biology Technology:A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 2A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 3SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3North Shore Towers Partners with GI Energy to Install Turnkey Natural Gas-Fired Combined Heat and Power Plant 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16
... in German . , A mystical glow ... of nowhere. And a light source is invisible at ... source of the apparently supernatural illumination become visible: a light ... lens structures measuring only a few hundred nanometers, et voil: ...
... ... their complexity and substantial potential benefits for sponsors and patients. In Medelis, new issue ... of the adaptive trial model and the latest thinking about its application in phase I ... ...
... , AMSTERDAM ... today,announced that it has signed two commercial manufacturing agreements with ... process validation and GMP commercial manufacturing services to,support the commercial ... SynCo has commenced with preparations for ...
Cached Biology Technology:Nano for the senses 2Nano for the senses 3Adaptive Trial Paper Explores Benefits of Adaptive Trials for Phase I, Phase II Studies 2Adaptive Trial Paper Explores Benefits of Adaptive Trials for Phase I, Phase II Studies 3Adaptive Trial Paper Explores Benefits of Adaptive Trials for Phase I, Phase II Studies 4SynCo Bio Partners Signs New Manufacturing Agreements to Supply the US Market; Securing its Position as a Market Leader in Microbial Biopharmaceutical Contract Production 2
(Date:8/1/2014)... the fossil record about 200,000 years ago, but it ... and advanced tools became widespread. , A new ... Anthropology finds that human skulls changed in ways ... the same time that culture was blossoming. , "The ... rapid cultural exchange probably came at the same time ...
(Date:8/1/2014)... research will provide enormous opportunities for both biological ... replicate any other cells in the body, offering ... spinal cords, treating kidney, liver and lung diseases ... profit is staggering. Prof. Jinhui Chen from Indiana ... research still faces myriad biological, ethical, legal, political, ...
(Date:8/1/2014)... a more effective way to control the condition, thanks ... National University of Singapore (NUS). , The team, led ... Pharmacology at the NUS Yong Loo Lin School of ... PhD graduate from the Saw Swee Hock School of ... herbal-based anti-malarial drug, can be used to control asthma, ...
Breaking Biology News(10 mins):Society bloomed with gentler personalities and more feminine faces 2NUS study shows effectiveness of common anti-malarial drug in controlling asthma 2
... drinks during team sports could help young people perform better, ... olds can play for longer in team games when they ... Researchers at the University of Edinburgh measured the performance ... demands of team games such as football, rugby and hockey. ...
... structural analysis, scientists at the Carnegie Institution,s Department of ... 192 square miles in the African savanna. They found ... and landscape patterns associated with annual rainfall. The results ... how termite mounds can be used to predict ecological ...
... New Rochelle, NY, September 7, 2010Publisher Mary ... Obesity to provide physicians, nurses, dietitians, diabetes ... organizers, and policymakers with effective prevention and treatment ... education and motivation tools, and clinical advances in ...
Cached Biology News:Energy drinks may give young sports teams an edge, study says 2Termites foretell climate change in Africa's savannas 2Premier issue of new Childhood Obesity journal launched by Mary Ann Liebert Inc., publishers 2Premier issue of new Childhood Obesity journal launched by Mary Ann Liebert Inc., publishers 3
... DMEM and harvested at the log phase of ... in their native forms, cells were fixed in ... 12-well (5 mm) adhesive coated slide, with each ... and to minimize background staining. Each well ...
... for optimal colony growth; ... growth of anchorage-dependent cells. ... colony-forming assays of human ... Not suitable for long-term ...
... Sample Buffer is a convenient, ... experimental samples and Perfect RNA ... needs no dilution and is ... gels. Simply mix equal volumes ...
... parameter assay for mitochondrial membrane potential ... caspases are detected by carboxyfluorescein (FAM)-labelled ... cell-permeable, non-cytotoxic and bind covalently to ... At the same time the mitochondrial ...
Biology Products: